This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): PAR-101, Difimicin, OPT-80, fidaxomicin, Dificlir (EU)
Description: Fidaxomicin is an inhibitor of the bacterial RNA polymerase. Its narrow-spectrum activity is highly selective for C. difficile, thus preserving gut microbial ecology.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Par Pharmaceutical and Optimer
In May 2005, Par Pharmaceutical entered into a joint development and collaboration agreement with Optimer Pharmaceuticals for the compound Difimicin. Under the terms of the agreement, Optimer will fund all expenses associated with the clinical trials of PAR-101. Par will be responsible for clinical development. All legal and regulatory responsibilities also reside with Par. Par will manufacture and market Difimicin. Par has exclusive rights to market, sell and distribute the product in the U.S. and Canada. Par will pay Optimer a royalty on sales of the product.
In February 2007, Par Pharmaceutical returned marketing rights to Difimicin to Optimer. For returning Difimicin marketing rights, Par received $20 million from Optimer. Under the terms of the agreement, Par will receive a $5 million milestone payment from Optimer upon the earliest of three events. Optimer is also obligated...See full deal structure in Biomedtracker
Partners: Endo International plc Astellas Pharma, Inc. Specialised Therapeutics Australia Pty, Ltd. AstraZeneca PLC OBI Pharma, Inc.
Pink Sheet Dificid Launch On Path To Success
Additional information available to subscribers only: